

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): **April 7, 2015**

Ekso Bionics Holdings, Inc.
(Exact Name of Registrant as specified in its charter)

Nevada
(State or Other Jurisdiction of
Incorporation)

333-181229
(Commission File Number)

99-0367049
(IRS Employer
Identification No.)

1414 Harbour Way South, Suite 1201
Richmond, California 94804
(Address of principal executive offices, including zip code)

(203) 723-3576
(Registrant's telephone number, including area code)

Not Applicable
(Registrant's name or former address, if change since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On April 7, 2015, the Board of Directors of Ekso Bionics Holdings, Inc. (the “Company”) voted to expand the number of directors of the Company from six to seven directors and elected Amy McBride Wendell to serve as a director of the Company.

Ms. Wendell will participate in the Company’s standard non-employee director compensation program. Pursuant to this program, Ms. Wendell was awarded an option to purchase 200,000 shares of common stock that becomes exercisable over a period of four years. In addition, each non-employee director is entitled to receive a \$10,000 annual retainer as well as a \$5,000 annual retainer for each Committee of the Board on which he or she serves. It also is anticipated that Ms. Wendell will enter into the Company’s standard indemnification agreement for directors of the Company.

On April 8, 2015, the Company issued a press release announcing the appointment of Ms. Wendell. A copy of the press release is filed with this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release dated April 8, 2015

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

EKSO BIONICS HOLDINGS, INC.

By: /s/ Nathan Harding

Name: Nathan Harding

Title: Chief Executive Officer

Dated: April 10, 2015

FOR IMMEDIATE RELEASE

AMY WENDELL JOINS EKSO BIONICS BOARD OF DIRECTORS

Ekso Bionics adds former Covidien Senior Vice President as company builds momentum in healthcare sector

RICHMOND, CA, April 8, 2015 – Ekso Bionics Holdings, Inc. (OTCQB: EKSO) today announced that Amy Wendell, former Senior Vice President, Strategy and Business Development of Covidien, global health care products company and manufacturer of medical devices and supplies, has been elected to Ekso Bionics' board of directors.

“At Covidien, Amy Wendell presided over an impressive acquisition strategy, acquiring more than 100 companies with leading edge technologies across many healthcare sectors. She has combed through an incredible number of growth strategies and understands the ones that really make sense,” said Nathan Harding, chief executive officer and co-founder. “We look forward to benefiting from Amy's operational and product management experience as well as her strategic acumen.”

“We were dedicated to finding a board member with all of the attributes that Amy Wendell embodies for over a year now and we are proud to welcome such an exceptional individual,” said Steven Sherman, Ekso Bionics' chairman. “I am confident that Amy is going to make a significant and positive impact on our company.”

“I have a long time interest in medical device technology and, perhaps even more, the process of guiding innovative companies to make a positive impact in people's lives, hit business milestones and expand into new markets.” said Amy Wendell, a 29 year veteran at Covidien. “I am excited by what Ekso Bionics has begun to accomplish and I am honored to be joining their board.”

Since 1986, Amy Wendell has served in a range of leadership positions at Covidien, formerly known as Tyco Healthcare/Kendall, where she led the company's strategic planning and portfolio management functions, as well as all business development initiatives including M&A, integrations, equity investments, divestitures, licensing, distribution, and market intelligence. Amy received a bachelor's degree from Lawrence Institute of Technology (Mich.) and a master's degree in biomedical engineering from the University of Illinois.

Wendell's appointment increases the size of Ekso Bionics' board of directors to seven.

ABOUT EKSO BIONICS

Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product, called the Ekso GT robotic exoskeleton is intended to enable individuals with weakness or paralysis of the lower limbs, such as from spinal cord injury (SCI), stroke, and other conditions causing lower extremity weakness, to perform ambulatory functions such as gait training in rehabilitation institutions. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.

Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at www.eksobionics.com

Facebook: www.facebook.com/eksobionics

Twitter: @eksobionics

YouTube: <http://www.youtube.com/user/EksoBionics/>

FORWARD-LOOKING STATEMENTS

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.

###

Media Contact:

Heidi Darling, Director of Marketing Communications
Phone: 415.302.4777
hdarling@eksobionics.com

Investor Contact:

John Graziano, The Trout Group
Phone: 646.378.2942
jgraziano@troutgroup.com
